Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Thyroid Carcinoma, Anaplastic × sacituzumab govitecan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Breast Neoplasms 36 Triple Negative Breast Neoplasms 28 Carcinoma, Non-Small-Cell Lung 10 Urinary Bladder Neoplasms 9 Carcinoma, Transitional Cell 9 Neoplasm Metastasis 8 Lung Neoplasms 5 Endometrial Neoplasms 4 Brain Neoplasms 4 Small Cell Lung Carcinoma 3 Glioblastoma 3 Uterine Cervical Neoplasms 2 Salivary Gland Neoplasms 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Advanced Breast Cancer 2 Uterine Neoplasms 1 Urothelial Bladder Carcinoma 1 Triple Negative Locally Advanced Non-resectable Breast Cancer 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Recurrence 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Neoplasms 1

Interventions

trametinib 9 dabrafenib 9 Paclitaxel 9 pembrolizumab 4 fosbretabulin 4 lenvatinib 3 Sorafenib 3 Radiotherapy, Intensity-Modulated 3 efatutazone 2 combretastatin 2 cobimetinib 2 atezolizumab 2 aldesleukin 2 Vemurafenib 2 Trastuzumab 2 Radiotherapy 2 Gefitinib 2 Filgrastim 2 Everolimus 2 Doxorubicin 2 Docetaxel 2 Cisplatin 2 Carboplatin 2 zimberelimab 1 vandetanib 1 tumor necrosis factor-alpha, CNGRC fusion protein, human 1 tremelimumab 1 tislelizumab 1 tipifarnib 1 surufatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06235216 2024-11-01

SETHY

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Recruiting

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡